Cediranib
Recurrent Glioma
National Cancer Institute (NCI)Small moleculePhase 2Active
B
61/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 46/ 100
- Competitive Position
- 95/ 100
Competitive context
19 Active assets in the Recurrent Glioma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Tazemetostat National Cancer Institute (NCI) | Phase 2 | B |
Talzenna The University of Hong Kong | Phase 2 | B |
Palbociclib National Cancer Institute (NCI) | Phase 2 | B |
PI3K/MTOR INHIBITOR LY3023414 National Cancer Institute (NCI) | Phase 2 | B |
Larotrectinib National Cancer Institute (NCI) | Phase 2 | CCC |
View all 20 →
Same molecule, other indications
Cediranib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →